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Introduction
Comorbidity is a common and notable status concerning the 
increasing complexity of care associated with it. In developed 
countries, more than 50% of older adults have three or more 
chronic conditions1) and more than 20% of all patients were 
multimorbid.2) It has been suggested that managing multiple 
comorbidities requires more complex strategies to achieve effective 
care. However the prevalence estimates of multiple comorbidities 
differed significantly among studies.3)4)
The prevalence of comorbidity among people with hypertension 
is more common than those individuals with a normal BP. The 
comorbidity prevalence of hypertension has been estimated 
several times and estimates were inconsistent among publications 
from the government and those from academic societies.5) The 
marked differences of prevalence in several studies are due to the 
different reference population, the various study designs, inclusion 
of diseases categories, working definition of comorbidity, and 
representativeness of the data.
Among various routine data, information on several health 
statuses could be reflected better in health surveys than in 
medical records.6) Compared to other routine data, the KNHANES 
survey, which includes both a social and health status, could 
provide better representative prevalence estimates of diseases, 
including comorbidity with hypertension. The aim of the present 
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study is to estimate the prevalence of comorbidity among Korean 
hypertension patients based on the KNHANES.
Subjects and Methods
This study analyzed the data from the KNHANES IV-VI (2007-
2013). The KNHANES is a nationwide cross-sectional survey, 
conducted by the Korea Centers for Disease Control and Prevention 
(KCDC). The survey design, data collection, and detailed protocols in 
the KNHANES have been published.7) The survey chose a stratified 
and multistage clustered probability sampling method to select the 
representative households of Korean citizens who live in Korea. The 
KNHANES was initiated in 1998, was conducted tri-annually until 
2006 and converted to an annual survey from 2007 to 2013. The 
survey was designed to provide the representative statistics on 
the health and nutrition status of the Korean population and was 
composed of 3 major parts: health interview, health examination, 
and nutrition. Trained medical staff and interviewers collected 
information about the age, gender, socioeconomic status, education, 
insurance type and lifestyle. The questionnaires included history of 
several chronic diseases by a physician diagnosis and current use of 
agents for those diseases. The response rate varied between 70.2% 
and 86.5% for KNHANES I-VI.7) Among total 55,386 participants, 
only those who performed the survey on comorbidities completely 
were included. The data from 30092 adults, aged ≥30 yrs was used 
to analyze the prevalence of comorbidities among patient with 
hypertension.
Mobile examination centers and trained medical staff such as 
nurses measured the anthropometric and biochemical information. 
The standard protocol was adapted when measuring for blood 
pressure (BP), blood sample collection and biochemical analysis. 
After of at least 5 minutes of rest and in sitting position, BP was 
measured on the right arm by a mercury sphygmomanometer. To 
increase accuracy, BP was measured three times and the mean of 
the second and third BP was calculated. All samples were venous 
blood gatherings in the morning after an 8 hr fast. Since 2005, for 
quality control, the protocol applied to all laboratory analyses and 
laboratory data was monitored to meet the standards with validity 
and reliability. Hypertension was defined as an average SBP ≥140 
mmHg, DBP ≥90 mmHg or the presence of antihypertensive agents. 
Prehypertension was defined as an average SBP 120-139 mmHg or 
DBP 80-89 mmHg. Diabetes mellitus (DM) was defined as having 
a fasting plasma glucose ≥126 mg/dL, the current use of anti-
diabetic agents or the use of insulin prescribed by physician due to 
a previous diagnosis of diabetes. Impaired fasting glucose (IFG) was 
determined by the range; 100 mg/dL≤ fasting plasma glucose (FPG) 
<126 mg/dL. The diagnosis of hypercholesterolemia was defined as 
a total plasma cholesterol of ≥240 mg/dL after an 8 hour fast or 
current use of cholesterol-lowering agents. Hypertriglyceridemia 
was defined as triglyceride levels >200 mg/dL after a 12 hour fast. 
For the precise definition, KNHANES team released the triglyceride 
level of samples after a 12 hr fasting time and coded that of 
samples between 8 hr and 12 hr fast as a missing value. Hypo-
HDL-cholesterolemia was regarded as HDL-C levels <40 mg/dL, 
and hyper-LDL-cholesterolemia was considered as LDL-C levels 
>160 mg/dL. Dyslipidemia was defined as hypercholesterolemia, 
hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-
cholesterolemia.8) Body mass index (BMI) was calculated as body 
mass divided by the square of height (kg/m2). Obesity was considered 
as a BMI of ≥25 kg/m2, according to the WHO Asia–Pacific region 
guidelines, redefined for the Asian population.9) Central, or 
abdominal, obesity was regarded as a waist circumference (WC) ≥90 
cm for men and ≥85 cm for women. Obesity in logistic analysis was 
defined as obesity or central obesity. Stroke, myocardial infarction 
(MI), angina, chronic kidney disease (CKD), and thyroid disease were 
defined as being a previous diagnosis given by a physician. CVD 
was defined as the previous diagnosis of stroke, MI, or angina. 
Proteinuria was defined as a urine test strip ≥1+, azotemia as blood 
urea nitrogen (BUN) ≥18 mg/dL, and increased level of creatinine 
as serum creatinine (SCr) ≥1.6 mg/dL. Anemia was defined in 
accordance with WHO criteria:10) hemoglobin (Hb)<11.5 g/dL at 10-
11 yr; Hb<12.0 g/dL at 12-14 yr; <13.0 g/dL in males ≥15 yr; Hb<12.0 
g/dL among non-pregnant females ≥15 yr; and Hb<11.0 g/dL 
during pregnancy. Elevated liver enzyme was defined as aspartate 
aminotransferase >35 IU/L or alanine aminotransferase >40 IU/L. 
The number of comorbid diseases or multimorbidity was defined 
as the number of diseases among DM, obesity, dyslipidemia, CVD, 
CKD, thyroid disease, anemia, and liver function test abnormalities.
Survey procedures of the Statistical Analysis System program 
(SAS 9.3 Institute Inc., Cary, NC, USA) were used to perform 
the analysis of a complex sample data. The sampling weights 
were applied to all analyses in order for the results to represent 
the Korean population as a whole. Sampling weights were used 
to reflect a complex sample design, non-response rate, and 
post-stratification. A surveymeans procedure was used to find 
the prevalence of comorbidities related to hypertension, and a 
surveylogistic procedure was used concerning the association 
between comorbidities and hypertension. The results were 
presented with a weighted percentage and 95% confidence 
interval (CI)s. The results of association analysis were presented 
using odds ratio (OR) and 95% CI. Significance of the association 
between comorbidities and hypertension was tested through 
a surveylogistic regression analysis. Statistically significant 
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differences between effect estimates across strata of a potential 
effect modifier (e.g., the difference between male and female) were 
determined by calculating 95% CIs.11) Differences with a two-sided 
p-value of <.05 were considered statistically significant.
Results
Table 1 describes the demographic characteristics of subjects. 
Among a total of 30092 adults aged ≥30, the number of males 
(13358) were less than that of females (16734); the weighted 
percent for males was 51.2 (95% CI 50.7-51.7) and was larger than 
that for females; 48.8 (95% CI 48.3-49.3).
Hypertension patients had a higher proportion of comorbidity 
than adults with prehypertension in several diseases (Table 2). 
Prehypertension patients also tended to have a higher proportion 
of comorbidity than normal people without prehypertension. 
Obesity was 2.17 times (60.1%) more common among hypertension 
patients than among the normotensive group (27.7%). The 
prevalence of DM among people with hypertension (14.7%) was 
2.37 times higher than in adults without hypertension (6.2%). In 
addition, hypertension patients had a 1.51 times higher prevalence 
of dyslipidemia (57.6%) than adult with normal BP (38.1%). CVD 
prevalence was 3.6% for hypertension patients, which was 2.00 
times higher than the 1.8% for normotensive adults. Specifically, 
the prevalence of stroke was 3.40 times more common among 
adults with hypertension 1.7% than that among adults with 
normal BP 0.5%.
Among patients with 2 to 5 comorbid diseases and the more 
diseases an adult had, the prevalence was more common than for 
Table 1. Demographic characteristics of participants above 30 years old
Characteristics
Total (N=30092) Male (n=13358) Female (n=16734)
p
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Age group (years) <.001
30-39 6364 25.7 (24.8-26.6) 2873 27.7 (26.6-28.9) 3491 23.6 (22.6-24.5)
40-49 6482 27.4 (26.6-28.3) 3018 28.9 (27.8-30.0) 3464 25.9 (24.9-26.8)
50-59 6638 23.3 (22.6-24.0) 2812 22.8 (21.8-23.7) 3826 23.9 (23.1-24.7)
60-69 5923 13.6 (13.1-14.1) 2633 12.7 (12.1-13.3) 3290 14.7 (14.0-15.3)
70-79 4685 9.9 (9.5-10.4) 2022 8.0 (7.5-8.4) 2663 12.0 (11.4-12.6)
Marital status <.001
Single 1251 6.2 (5.8-6.6) 818 9.1 (8.3-9.8) 433 3.2 (2.8-3.5)
Married 24528 81.8 (81.1-82.5) 11803 85.7 (84.8-86.5) 12725 77.7 (76.8-78.5)
Widowed, divorced, and separated 4313 12.0 (11.5-12.5) 737 5.2 (4.8-5.7) 3576 19.1 (18.3-19.9)
Education level <.001
≤ Elementary school 5472 14.3 (13.6-14.9) 1408 7.9 (7.3-8.5) 4064 21.0 (20.1-21.9)
Middle school 5029 14.0 (13.5-14.6) 1941 11.7 (11.0-12.4) 3088 16.5 (15.8-17.2)
High school 7026 25.9 (25.1-26.7) 3288 26.3 (25.2-27.3) 3738 25.5 (24.6-26.4)
≥ College 12565 45.8 (44.7-46.9) 6721 54.1 (52.8-55.4) 5844 37.0 (35.8-38.2)
Household monthly income <.001
<25th 6253 16.4 (15.7-17.2) 2420 13.6 (12.8-14.3) 3833 19.5 (18.5-20.4)
25-49th 7622 25.9 (25.0-26.8) 3375 25.3 (24.3-26.4) 4247 26.5 (25.5-27.5)
50-75th 7989 28.5 (27.7-29.4) 3704 30.0 (29.0-31.0) 4285 27.0 (26.1-27.9)
≥75th 8228 29.1 (28.0-30.3) 3859 31.1 (29.8-32.4) 4369 27.1 (25.9-28.2)
Type of health insurance <.001
Medical aid 925 2.8 (2.4-3.1) 303 2.1 (1.8-2.4) 622 3.5 (3.0-3.9)
National Health Insurance 29167 97.2 (96.9-97.6) 13055 97.9 (97.6-98.2) 16112 96.5 (96.1-97.0)
Living area 0.543
Urban area 22638 78.6 (76.4-80.9) 10001 78.5 (76.2-80.8) 12637 78.8 (76.5-81.0)
Rural area 7454 21.4 (19.1-23.6) 3357 21.5 (19.2-23.8) 4097 21.2 (19.0-23.5)
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those adults with a normal BP (1.53, 2.89, 4.43, and 4.00 times higher 
prevalence, respectively). Patients with 3 or more comorbid diseases 
accounted for 17.7% (95% CI 16.3-19.2%) of hypertensive patients, 
which was 3.16 times more common than normotensive adults, 
5.6% (95% CI 5.1-6.1%). Among subjects with prehypertension, the 
prevalence of adults with 2 or more comorbid diseases was 29.8%, 
and those with 3 or more diseases was 9.9%. Among hypertensive 
patients, prevalence was 42.2% and 17.7%, respectively.
Male hypertensive patients had a higher prevalence of 
diseases including liver function test abnormalities, dyslipidemia, 
and impaired fasting glucose (Table 3). Meanwhile, hypo-HDL-
cholesterolemia, hypercholesterolemia, thyroid disease, anemia and 
central obesity were more common among female hypertensive 
patients than among males (data not shown). The prevalence 
of 1 or 2 comorbid diseases among female patients was higher 
than that among male patients. However, hypertensive patients 
without disease or with at least 3 diseases were more common 
among males than females. Although most of the difference in 
the prevalence of multimorbidity between both sexes was non-
significant, male hypertensive patients aged 30-39 (19.4±4.55%), 
40-49 (16.8±3.05%) and 50-59 (19.5±2.65%) had a significantly 
elevated prevalence compared to females (9.4±6.5%, 11.0±3.45%, 
13.5±2.20%), respectively (Fig. 1).
After adjustment for sex, age, marital status, education level, 
household income, smoking, alcohol drinking, exercise, type of 
insurance, and living area, the odds ratio was significantly elevated 
among hypertensive patients (Table 4). Hypertensive patients 
were more than 2 times as likely to have some comorbid diseases 
compared to adults without hypertension. ORs were for CKD; 3.94 
(95% CI 1.71-9.07), obesity; 2.60 (95% CI 2.43-2.78), CVD; 2.11 
(95% CI 1.78-2.50), DM; 2.22 (95% CI 2.02-2.45), liver function 
test abnormality; 1.82 (95% CI 1.65-2.01), comorbid diseases ≥3; 
2.63 (95% CI 2.37-2.92) and comorbid diseases ≥2; 2.10 (95% CI 
1.96-2.26). Hypertensive patients were also 1.74 times more likely 
to have dyslipidemia than those with a normal BP (95% CI 1.62-
1.88). Anemia and thyroid disease were not significantly different 
compared with adults without hypertension.
Discussion
The objective of the current study was to investigate the 
prevalence of comorbidity among Korean hypertensive patients 
based on the national representative survey. In this study, we 
Table 2. The prevalence of comorbid diseases among participants
Type of comorbid diseases
Normal (n=13167) Prehypertension (n=7100) Hypertension (n=9825)
p
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Obesity 3513 27.7 (26.8-28.7) 2931 43.0 (41.5-44.5) 5369 60.1 (58.2-61.9) <.001
Diabetes mellitus 694 6.2 (5.7-6.7) 718 8.8 (8.0-9.6) 2070 14.7 (13.7-15.8) <.001
Impaired fasting glucose 2601 21.6 (20.7-22.5) 2428 32.7 (31.2-34.1) 4913 45.1 (43.3-47.0) <.001
Dyslipidemia 3861 38.1 (36.9-39.2) 2738 47.0 (45.3-48.6) 4860 57.6 (55.4-59.7) <.001
Cardiovascular disease 187 1.8 (1.5-2.1) 187 1.9 (1.6-2.3) 731 3.6 (3.2-4.0) <.001
Stroke 60 0.5 (0.4-0.7) 61 0.6 (0.4-0.8) 327 1.7 (1.4-2.0) <.001
Myocardial infarction 58 0.6 (0.4-0.8) 44 0.5 (0.3-0.6) 137 0.7 (0.5-0.9) <.001
Angina 84 0.8 (0.6-1.0) 86 0.9 (0.7-1.1) 308 1.4 (1.2-1.6) <.001
Chronic kidney disease 11 0.1 (0.02-0.2) 8 0.1 (0.02-0.2) 43 0.4 (0.1-0.6) <.001
Liver function test abnormality 1264 10.4 (9.7-11.0) 1201 18.9 (17.7-20.1) 1690 26.3 (24.5-28.0) <.001
Thyroid disease 288 2.0 (1.7-2.3) 136 1.4 (1.1-1.7) 195 1.5 (1.0-1.9) 0.20
Anemia 1426 9.9 (9.3-10.5) 467 5.6 (5.0-6.2) 892 5.6 (5.0-6.2) <.001
Number of comorbid diseases <.001
0 6780 50.4 (49.3-51.5) 2958 43.9 (42.4-45.4) 2922 35.2 (33.2-37.1) <.001
1 3752 27.9 (27.0-28.9) 1960 26.3 (25.0-27.6) 2448 22.7 (21.1-24.3) <.001
2 1956 16.0 (15.2-16.8) 1472 19.9 (18.7-21.1) 2588 24.5 (22.9-26.0) <.001
≥3 679 5.6 (5.1-6.1) 710 9.9 (9.0-10.8) 1867 17.7 (16.3-19.2) <.001
The number of comorbid diseases was defined by the number of diseases among diabetes mellitus, obesity, dyslipidemia (hypercholesterolemia, hypertri-
glyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia), cardiovascular disease (stroke, myocardial infarction, or angina), CKD, thyroid dis-
ease, anemia, and liver function test abnormalities. HDL: high density lipoprotein, LDL: low density lipoprotein, CKD: chronic kidney disease 
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compared the prevalence of comorbid diseases and multimorbidity 
in hypertensive patients among adults aged ≥30 years, using 
KNHANES 2007-2013.
Although several studies to estimate the prevalence of 
comorbidity among hypertension patients have been undertaken, 
the estimates have not yet been fully established and are still 
controversial between publications from the government 
and academic society. The prevalence estimates of multiple 
comorbidities also differ significantly among studies3)4) and the 
definition of it is still the subject of controversy. Even in Korea, 
the estimates of multimorbidity among hypertensive patients 
were different depending on the source of the data. The marked 
differences in several studies are due to the various study designs, 
inclusion of diseases, working definition of multimorbidity, and 
Table 3. The prevalence of comorbid diseases among participants, stratified by gender
Type of comorbid diseases
Normal 
(Male 4916, Female 8251)
Prehypertension
(Male 3785, Female 3315)
Hypertension
(Male 4657, Female 5168) p
N Percent (95% CI) N Percent (95% CI) N Percent (95% CI)
Male
Obesity 1471 29.8 (28.3-31.2) 1576 43.4 (41.6-45.3) 2445 59.9 (57.8-62.0) <.001
Diabetes mellitus 379 8.2 (7.3-9.1) 406 9.3 (8.3-10.4) 988 15.4 (14.1-16.7) <.001
Impaired fasting glucose 1280 26.5 (25.1-28.0) 1433 35.7 (33.9-37.6) 2519 48.1 (45.9-50.2) <.001
Dyslipidemia 1768 47.3 (45.4-49.2) 1487 50.0 (47.8-52.2) 2235 60.2 (57.6-62.8) <.001
Cardiovascular disease 113 2.4 (1.9-2.9) 112 2.3 (1.8-2.8) 356 4.0 (3.4-4.5) <.001
Chronic kidney disease 4 0.1 (0.0-0.1) 5 0.1 (0.0-0.3) 17 0.4 (0.04-0.7) <.01
Liver function test abnormality 865 17.4 (16.2-18.7) 893 23.7 (22.1-25.4) 1130 31.7 (29.6-33.9) <.001
Thyroid disease 32 0.5 (0.3-0.7) 24 0.5 (0.2-0.7) 23 0.3 (0.1-0.5) 0.49
Anemia 174 3.5 (2.9-4.1) 127 2.7 (2.1-3.2) 269 3.2 (2.6-3.8) <.001
Number of comorbid disease
0 2447 50.0 (48.3-51.6) 1616 44.3 (42.4-46.2) 1560 37.1 (34.9-39.4) <.001
1 1256 25.1 (23.7-26.5) 991 25.3 (23.6-26.9) 1050 20.4 (18.6-22.1) <.001
2 863 18.0 (16.8-19.3) 764 19.8 (18.3-21.3) 1137 23.5 (21.7-25.3) <.001
≥3 350 6.9 (6.1-7.7) 414 10.6 (9.4-11.8) 910 19.0 (17.3-20.8) <.001
Female
Obesity 2042 26.5 (25.3-27.8) 1355 39.4 (37.0-41.8) 2924 55.5 (51.6-59.5) <.001
Diabetes mellitus 315 4.6 (4.0-5.2) 312 8.2 (7.0-9.5) 1082 14.7 (12.3-17.1) <.001
Impaired fasting glucose 1321 17.8 (16.7-18.9) 995 28.5 (26.3-30.6) 2394 41.3 (37.2-45.3) <.001
Dyslipidemia 2093 31.9 (30.6-33.2) 1251 40.6 (38-43.2) 2625 50.3 (46.0-54.6) <.001
Cardiovascular disease 74 1.3 (0.9-1.6) 75 1.5 (1.1-1.9) 375 3.6 (2.6-4.6) <.001
Chronic kidney disease 7 0.1 (0.0-0.2) 3 0.1 (0.0-0.1) 26 0.3 (0.1-0.5) <.001
Liver function test abnormality 399 4.8 (4.2-5.4) 308 9.3 (7.8-10.8) 560 11.2 (8.8-13.5) <.001
Thyroid disease 256 3.1 (2.7-3.6) 112 2.9 (2.1-3.6) 172 4.4 (2.1-6.7) 0.61
Anemia 1252 15 (14-15.9) 340 12.1 (10.5-13.7) 623 10.9 (8.8-13.1) <.001
Number of comorbid diseases
0 4333 50.6 (49.3-52.0) 1342 44.0 (41.5-46.5) 1362 31.8 (28.1-35.5) <.001
1 2496 30.2 (28.9-31.4) 969 28.0 (25.8-30.2) 1398 29.5 (25.6-33.4) 0.02
2 1093 14.5 (13.6-15.5) 708 19.8 (17.9-21.7) 1451 25.3 (21.8-28.8) <.001
≥3 329 4.7 (4.1-5.3) 296 8.2 (6.9-9.5) 957 13.4 (11.1-15.7) <.001
The number of comorbid diseases was defined by the number of diseases among diabetes mellitus, obesity, dyslipidemia (hypercholesterolemia, hypertri-
glyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia), cardiovascular disease (stroke, myocardial infarction, or angina), CKD, thyroid dis-
ease, anemia, and liver function test abnormalities. HDL: high density lipoprotein, LDL: low density lipoprotein, CKD: chronic kidney disease 
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Fig. 1. The prevalence of comorbidity ≥2 diseases (A, C) and ≥3 diseases (B, D) and 95% confidence intervals among people with hypertension by sex and 
age group. *p<0.05, †p<0.10.
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Table 4. Adjusted odds ratios with 95% confidence interval for comorbidity conditions in women and men with hypertension
Type of comorbid diseases
Total Male Female
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Chronic kidney disease 3.94 (1.71-9.07) <.001 3.86 (1.21-12.32) 0.02 3.47 (1.05-11.48) 0.04
Obesity 2.60 (2.43-2.78) <.001 2.67 (2.43-2.94) <.001 2.28 (2.07-2.51) <.001
Cardiovascular disease 2.11 (1.78-2.50) <.001 1.86 (1.48-2.35) <.001 2.45 (1.88-3.18) <.001
Diabetes mellitus 2.22 (2.02-2.45) <.001 2.03 (1.78-2.30) <.001 2.44 (2.11-2.82) <.001
Liver function test abnormality 1.82 (1.65-2.01) <.001 1.78 (1.58-2.01) <.001 1.70 (1.42-2.04) <.001
Dyslipidemia 1.74 (1.62-1.88) <.001 1.70 (1.53-1.89) <.001 1.68 (1.51-1.88) <.001
Anemia 0.88 (0.79-0.99) 0.03 1.03 (0.81-1.31) 0.80 0.92 (0.81-1.05) 0.22
Thyroid disease 0.89 (0.70-1.14) 0.35 0.63 (0.33-1.19) 0.16 0.95 (0.72-1.25) 0.71
Number of comorbid diseases ≥3 2.63 (2.37-2.92) <.001 2.63 (2.29-3.01) <.001 2.37 (2.03-2.76) <.001
Number of comorbid diseases ≥2 2.10 (1.96-2.26) <.001 2.00 (1.82-2.21) <.001 2.08 (1.87-2.30) <.001
Adjusted for sex (only in total), age, marital status, education level, household income, smoking status, alcohol drinking, exercise, type of insurances, and 
living area. The number of comorbid diseases was defined by the number of diseases among diabetes mellitus, obesity, dyslipidemia (hypercholesterolemia, 
hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia), cardiovascular disease (stroke, myocardial infarction, or angina), CKD, 
thyroid disease, anemia, and liver function test abnormalities. HDL: high density lipoprotein, LDL: low density lipoprotein, CKD: chronic kidney disease 
A
C
B
D
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representativeness of the data.
Among the study population, the prevalence of hypertension 
(27.4 for total, 30.6% for male and 23.5% for female) was 
relatively lower than the result (56.0% for total) of the research 
by the Working Group of the Italian Society of Hypertension12) 
or the findings (52.4% for male and 37.8% for female) in the 
Progetto CUORE cohort study by the Italian Ministry of Health.13) 
The prevalence of acute myocardial infarction, stroke, and angina 
pectoris were similar to that in the Progetto CUORE cohort study 
(0.9, 1.2, and 1.1% for male and 0.3, 0.8, and 1.1% for female.
In agreement with similar studies,14-16) common comorbidities 
of hypertensive patients were dyslipidemia, obesity, and impaired 
fasting glucose. Seven of the eight chronic conditions were 
more prevalent in hypertensive patients than in adults without 
hypertension. Among hypertension patients aged ≥30 years, 
64.8% suffer from 1 or more comorbidities, 42.2% from 2 or more 
diseases, and 17.7% had 3 or more comorbidities. Comorbidity 
was more common among adults with hypertension than among 
those without high BP. Male hypertensive patients with 3 or more 
diseases were more common than female patients. The results 
of the present study correspond well with those found in earlier 
studies that stated comorbidity proportions of several diseases 
tended to be the highest among hypertensive patients, following 
prehypertension and normal people without prehypertension.17) 
The results of the present study correspond well with those found 
in the earlier systematic review which reported that multimorbidity 
influence more than half of the elderly population.4) These 
results expanded upon previous multimorbidity studies of adults, 
elucidating the high prevalence of multimorbidity in adults with 
hypertension.
Stratified by age and sex, male hypertensive patients aged 
30-59 had a significantly higher prevalence of multimorbidity 
≥3 than female patients. This finding is similar to another study 
that stated the age and sex-specific prevalence of multimorbidity, 
more than 2 comorbidities, showed a marked difference among 
young hypertensive patients; the gap declined until age 70 and 
only between ages 70-79 did the prevalence among females 
exceed that among males.18) These findings might be attributed 
to the disparities in the diagnosis and treatment, which has been 
discussed in other studies.19)20) In terms of the prevalence of 
multimorbidity≥2, female patients aged 60-79 had significantly 
higher estimates than male patients. Several studies have shown 
a higher prevalence of multimorbidity, more than 1 comorbid 
disease, among females compared to males. This could possibly be 
due to a longer life expectancy and the biological and social status 
related with a declining health status of females.21)22)
In an association analysis, the results of the present study are 
similar to the previous report.23) After adjustment for age, sex, 
marital status, socioeconomic status, insurance, and living area, 
hypertension had a positive association with the risk of multiple 
comorbidities. Stratified by sex among hypertensive patients, the 
risk for comorbidity was different without statistical significance. 
Only the risk for obesity was statistically significantly higher among 
males than among females.
The current study has several limitations. First, the study 
population could be different from general hypertensive patients. 
The KNHANES cannot include institutionalized patients and the 
result could underestimate severe diseases and the prevalence of 
CKD. That is, KNHANES represents the non-institutionalized general 
population among Korean citizens. In addition, the target population 
of this study did not include all hypertensive patients with chronic 
diseases but only those with 8 diseases, which are known to be 
hypertensive related diseases. The prevalence of hypertension in 
this study is different from that of Korea health statistics due to 
the difference of the study population.24) However, if we used the 
same inclusion criteria for the target population, the prevalence 
estimates would be the same. Second, the working definition 
of some diseases could be different from the diagnosis criteria. 
Several comorbidities were defined by just 1 laboratory test result 
and the prevalence might be overestimated due to a possible false 
positive. Other diseases defined by the current prevalence could be 
underestimated due to the response rate of questionnaires, varying 
between 70.2% and 86.5% for KNHANES I-VI.7) Third, the present 
study was a cross-sectional analysis and could not investigate the 
factors affecting the prevalence for comorbidities among adults 
with hypertensive. Fourth, the laboratory and some of the methods 
for measuring blood concentrations were changed, so glucose and 
cholesterol level could influence the results of related diseases such 
as DM or dyslipidemia. However, KCDC attempted to control the 
quality with a parallel test of the laboratory analysis, to maintain 
the blood analysis stability, and to suggest the transformation 
equation.
Although there are several limitations, the present study 
estimated the prevalence and risk of comorbidity among 
hypertensive patients based on a continuous survey with nationally 
representative samples of Korean citizens through health interviews, 
physical examinations and nutrition surveys (KNHANES). KCDC 
and related academic societies have managed external quality 
control programs for all steps (including survey administration, 
data collection, laboratory analysis and data processing) as well 
as internal quality assurance and control procedures. The present 
study could provide national representative descriptive statistics 
for the care of hypertensive patients with complex comorbid 
conditions.
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The KNHANES was from a quality controlled and standardized 
survey with a nation-wide representative sample of Korea. We 
specified the national prevalence estimate of comorbidity among 
hypertensive patients. In summary, comorbid diseases were 
common in Korean hypertensive patients and increased with age 
in both sexes. About 44% of patients with hypertension had at 
least two comorbidities and 17% had at least three comorbidities. 
Physicians should have special considerations during the evaluation 
of patients with comorbidity and hypertension to provide better 
comprehensive care.
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